
Neuroimaging Market Global Industry Analysis and Forecast (2024-2032) by Technology (Magnetic Resonance Imaging (MRI), Computed Tomography (CT), Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT), Functional Magnetic Resonance Imaging (fMRI) and Others), Application (Neurological Disorders, Psychiatric Disorders, Traumatic Brain Injury), End User (Hospitals and Clinics, Diagnostic Centers, Research Institutes, Ambulatory Surgical Centers, and Others) and Region
Neuroimaging Market Size Was Valued at USD 14.24 Billion in 2023 and is Projected to Reach USD 24.26 Billion by 2032, Growing at a CAGR of 6.1 % From 2024-2032.
Neuroimaging is a specialized branch of medical imaging that focuses on the brain. It extends beyond just diagnosing illnesses and evaluating the health of the brain to explore how the brain operates and how various activities impact it.
Top Active Players:
Varian Medical Systems (USA), General Electric Company (GE) (USA), NeuroLogica Corporation (USA), NeuroVista (USA), Positron Corporation (USA), Trefoil Imaging (USA), Siemens AG (Germany), Philips Healthcare (Netherlands), Brainlab AG (Germany), Brainomix Ltd. (UK), Mevis Medical Solutions (Germany), EB Neuro S.p.A. (Italy), Neurosoft (Russia), Toshiba Medical Systems (Japan), Hitachi Medical Systems (Japan), Canon Medical Systems Corporation (Japan), Esaote SpA (Italy), Mindray Medical International Limited (China), Neusoft Medical Systems (China), Shimadzu Corporation (Japan) and Other Active Players
Neuroimaging Market Segmented based on Technology, Application, and End-users.
In March 2024, Cortechs.AI launched NeuroQuant version 5.0 for neuroimaging, which was pending U.S. FDA 510(k) approval at the time of release. This update improved the precision of neuroimaging in diagnosing and monitoring neurological disorders, according to company officials. The new version aimed to provide more accurate and reliable data for healthcare professionals, enhancing their ability to track the progression of neurological conditions.
In March 2024, Neurophet, an artificial intelligence (AI) solution company specializing in brain disease, introduced its AI-powered brain imaging analysis technology at the international conference on Alzheimer's and Parkinson's diseases and related neurological disorders (AD/PD 2024). The event showcased innovative advancements in neurological research and treatment. Neurophet's participation highlighted its commitment to leveraging AI for improved diagnosis and management of brain diseases.
Global Neuroimaging Market |
|||
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 14.24 Bn. |
Forecast Period 2024-32 CAGR: |
6.1 % |
Market Size in 2032: |
USD 24.26 Bn. |
Segments Covered: |
By Technology |
|
|
By Application |
|
||
By End-User |
|
||
By Region |
|
Global Neuroimaging Market |
|||
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 14.24 Bn. |
Forecast Period 2024-32 CAGR: |
6.1 % |
Market Size in 2032: |
USD 24.26 Bn. |
Segments Covered: |
By Technology |
|
|
By Application |
|
||
By End-User |
|
||
By Region |
|
||
Key Market Drivers: |
|
||
Key Market Restraints: |
|
||
Key Opportunities: |
|
||
Companies Covered in the report: |
|
The forecast period in the Neuroimaging Market research report is 2024-2032.
Varian Medical Systems (USA), General Electric Company (GE) (USA), NeuroLogica Corporation (USA), NeuroVista (USA), Positron Corporation (USA), Trefoil Imaging (USA), Siemens AG (Germany), Philips Healthcare (Netherlands), Brainlab AG (Germany), Brainomix Ltd. (UK), Mevis Medical Solutions (Germany), EB Neuro S.p.A. (Italy), Neurosoft (Russia), Toshiba Medical Systems (Japan), Hitachi Medical Systems (Japan), Canon Medical Systems Corporation (Japan), Esaote SpA (Italy), Mindray Medical International Limited (China), Neusoft Medical Systems (China), Shimadzu Corporation (Japan) and Other Active Players and Other Major Players.
The Neuroimaging Market is segmented into Technology, Application, End-User, and region. By Technology, the market is categorized into Magnetic Resonance Imaging (MRI), Computed Tomography (CT), Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT), Functional Magnetic Resonance Imaging (fMRI), and Others. By Application, the market is categorized into Neurological Disorders, Psychiatric Disorders, and Traumatic Brain Injury. By End-User, the market is categorized into Hospitals and Clinics, Diagnostic Centers, Research Institutes, Ambulatory Surgical Centers, and Others. By region, it is analyzed across North America (U.S.; Canada; Mexico), Eastern Europe (Bulgaria; The Czech Republic; Hungary; Poland; Romania; Rest of Eastern Europe), Western Europe (Germany; UK; France; Netherlands; Italy; Russia; Spain; Rest of Western Europe), Asia-Pacific (China; India; Japan; Southeast Asia, etc.), South America (Brazil; Argentina, etc.), Middle East & Africa (Saudi Arabia; South Africa, etc.).
Neuroimaging is a specialized branch of medical imaging that focuses on the brain. It extends beyond just diagnosing illnesses and evaluating the health of the brain to explore how the brain operates and how various activities impact it. By utilizing quantitative methods, neuroimaging provides a scientific and non-invasive way to study the healthy human brain objectively. This interdisciplinary area integrates neuroscience, computer science, psychology, and statistics to enable rigorous studies of brain structure and function.
Neuroimaging Market Size Was Valued at USD 14.24 Billion in 2023 and is Projected to Reach USD 24.26 Billion by 2032, Growing at a CAGR of 6.1 % From 2024-2032.